

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 under
the Securities Exchange Act of 1934**

For the month ended October, 2008

ICON plc
(Registrant's name)

0-29714
(Commission file number)

South County Business Park, Leopardstown, Dublin 18, Ireland
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Yes No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82 **N/A**

EXHIBIT LIST

<u>Exhibit</u>	<u>Description</u>
99.1	Icon plc Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ICON plc

Date: October 21, 2008

/s/ Ciaran Murray
Ciaran Murray
Chief Financial Officer

Icon Reports 35% Increase in Revenue and 45% Increase in Operating Income

Highlights – Third Quarter Fiscal 2008

- **Net revenues increased 35%, to \$225.5 million**
- **Income from operations increased by 45%, to \$27.1 million**
- **Operating margin increased to 12% from 11.2%**
- **Diluted earnings per share increased by 46% to 35 cents**
- **Net new business wins were \$350 million, a book-to-bill of 1.6x**

DUBLIN, Ireland--(BUSINESS WIRE)--October 21, 2008--ICON (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for its third quarter ended September 30, 2008.

Net revenues for the quarter were \$225.5 million, representing a 35.1% increase over net revenues of \$166.9 million for the comparative quarter last year. Year-to-date, net revenues were \$645.2 million, representing a 43.4% increase over the same period last year.

Income from operations was \$27.1 million, compared to \$18.7 million for the same quarter last year. Operating margin increased to 12.0% from 11.2%. Net income was \$21.4 million or 35 cents per share on a diluted basis, compared with \$14.5 million or 24 cents per share last year.

Year-to-date income from operations was \$73.0 million, compared to \$49.5 million last year representing an operating margin increase to 11.3% from 11.0%. Net income was \$57.1 million or 93 cents per share, compared with \$40.1 million or 67 cents last year.

Days sales outstanding were 54 days at September 30, 2008, compared to 66 days at December 31, 2007.

For the quarter ended September 30, 2008, cash provided by operating activities was \$58 million and capital expenditure was \$18.1 million. As a result, the company's net cash amounted to \$55.6 million at September 30, 2008, compared to net cash of \$6.9 million at June 30, 2008.

"We are pleased with our continued strong progress" said Chairman, Dr. John Climax, " Revenues and operating profits for the first nine months of 2008, at \$645 million and \$73 million respectively, already exceed those achieved in all of 2007. Year-to-date new business bookings, at over \$1bn, have also surpassed those of the full year 2007 "

Commenting on the quarter, CEO Peter Gray said " With revenues for the quarter up 35%, margins up to 12%, EPS up 46%, and strong operating cash generation, we are very satisfied with our performance in the quarter. ICON's strategy of listening to its customers and delivering the services they need, where and when they need them, continues to be validated. With net new business awarded in the quarter of \$350 million and our backlog now at over \$1.74 billion, we are confident in the outlook for the remainder of 2008 and view 2009 with optimism"

The company will hold its third quarter conference call today, October 21, 2008 at 9:00 EST [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at <http://www.iconplc.com>. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under "Investors". This calendar will be updated regularly.

The statements made in this Press Release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this Press Release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

The financial information presented herein has been prepared in accordance with U.S. GAAP.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 71 locations in 38 countries and has approximately 6,600 employees. Further information is available at www.iconplc.com.

ICON plc

Consolidated Income Statements (Unaudited)

Three and Nine Months ended September 30, 2008 and September 30, 2007
(Dollars, in thousands, except share and per share data)

	Three Months Ended		Nine Months Ended	
	September 30, 2008	September 30, 2007	September 30, 2008	September 30, 2007
Gross Revenue	313,637	231,819	914,082	625,942
Subcontractor costs	88,126	64,903	268,927	175,890
Net Revenue	<u>225,511</u>	<u>166,916</u>	<u>645,155</u>	<u>450,052</u>
Costs and expenses				
Direct costs	127,948	91,675	364,113	254,107
Selling, general and administrative	62,494	51,518	187,328	132,864
Depreciation and amortization	7,937	5,020	20,676	13,626
Total costs and expenses	<u>198,379</u>	<u>148,213</u>	<u>572,117</u>	<u>400,597</u>
Income from operations	27,132	18,703	73,038	49,455
Interest (expense) income	(224)	16	(743)	2,079
Income before provision for income taxes	<u>26,908</u>	<u>18,719</u>	<u>72,295</u>	<u>51,534</u>
Provision for income taxes	5,355	4,158	14,493	11,344
Minority interest	173	60	707	108
Net income	<u>21,380</u>	<u>14,501</u>	<u>57,095</u>	<u>40,082</u>
Net income per ordinary share				
Basic	<u>\$0.37</u>	<u>\$0.25</u>	<u>\$0.98</u>	<u>\$0.70</u>
Diluted	<u>\$0.35</u>	<u>\$0.24</u>	<u>\$0.93</u>	<u>\$0.67</u>
Weighted average number of ordinary shares				
Basic	58,451,960	57,521,452	58,156,869	57,339,596
Diluted	61,847,265	59,652,914	61,357,893	59,429,170

ICON plc

Summary Balance Sheet Data

September 30, 2008 and December 31, 2007
(Dollars, in thousands)

	September 30, 2008 (Unaudited)	December 31, 2007 (Audited)
Cash and short-term investments	135,154	118,633
Debt	(79,547)	(94,829)
Net cash	55,607	23,804
Accounts receivable	179,553	129,865
Unbilled revenue	138,864	144,661
Payments on account	(129,030)	(96,553)
Total	189,387	177,973
Working Capital	204,755	193,271
Total Assets	808,656	693,138
Shareholder's Equity	452,077	388,400

Source: ICON plc

Contact: Investor Relations 1-888-381-7923 or
Ciaran Murray CFO + 353 1 291 2000
both at ICON.

<http://www.iconplc.com>

CONTACT:
ICON plc
Investor Relations 1-888-381-7923
or
Ciaran Murray, CFO
+353 -1-291-2000